Annex
United Kingdom
Table 3.1 of Part 3 of Annex VI to Regulation (EC) No 1272/2008 is amended as follows:
- (a)
the entries corresponding to index numbers 607-331-00-5 and 609-066-00-0 are deleted;
- (b)
the entries corresponding to index numbers, 006-035-00-8, 029-002-00-X, 602-020-00-0, 602-033-00-1, 603-055-00-4, 604-030-00-0, 604-092-00-9, 605-013-00-0, 605-022-00-X, 606-014-00-9, 606-021-00-7, 607-056-00-0, 607-059-00-7, 607-157-00-X, 607-172-00-1, 607-375-00-5, 607-623-00-2, 613-166-00-X, 613-121-00-4, 616-011-00-4, 616-037-00-6 and 616-207-00-X are replaced by the following entries respectively:
Index No International Chemical Identification EC No CAS No Classification Labelling Specific Conc. Limits, M-factors Notes Hazard Class and Category Code(s) Hazard statement Code(s) Pictogram, Signal Word Code(s) Hazard statement Code(s) Suppl. Hazard statement Code(s) ‘006-035-00-8 pirimicarb (ISO); 2-(dimethylamino)-5,6-dimethylpyrimidin-4-yl dimethylcarbamate 245-430-1 23103-98-2 Carc. 2
Acute Tox. 3
Acute Tox. 3
Skin Sens. 1
Aquatic Acute 1 Aquatic Chronic 1
H351
H331
H301
H317
H400
H410
GHS08
GHS06
GHS09
Dgr
H351
H331
H301
H317
H410
M = 10
M = 100’
‘029-002-00-X dicopper oxide;
copper (I) oxide
215-270-7 1317-39-1 Acute Tox. 4
Acute Tox. 4
Eye Dam. 1
Aquatic Acute 1
Aquatic Chronic 1
H332
H302
H318
H400
H410
GHS07
GHS05
GHS09
Dgr
H332
H302
H318
H410
M = 100’ ‘602-020-00-0 1,2-dichloropropane;
propylene dichloride
201-152-2 78-87-5 Flam. Liq. 2
Carc. 1B
Acute Tox. 4*
Acute Tox. 4*
H225
H350
H332
H302
GHS02
GHS08
GHS07
Dgr
H225
H350
H332
H302’
‘602-033-00-1 chlorobenzene 203-628-5 108-90-7 Flam. Liq. 3
Acute Tox. 4
Skin Irrit. 2
Aquatic Chronic 2
H226
H332
H315
H411
GHS02
GHS07
GHS09
Wng
H226
H332
H315
H411’
‘603-055-00-4 propylene oxide;
1,2-epoxypropane; methyloxirane
200-879-2 75-56-9 Flam. Liq. 1
Carc. 1B
Muta. 1B
Acute Tox. 3
Acute Tox. 3
Acute Tox. 4
STOT SE 3
Eye Irrit. 2
H224
H350
H340
H331
H311
H302
H335
H319
GHS02
GHS08
GHS06
Dgr
H224
H350
H340
H331
H311
H302
H335
H319’
‘604-030-00-0 bisphenol A;
4,4′-isopropylidenediphenol
201-245-8 80-05-7 Repr. 1B
STOT SE 3
Eye Dam. 1
Skin Sens. 1
H360F
H335
H318
H317
GHS08
GHS05 GHS07
Dgr
H360F
H335
H318
H317’
‘604-092-00-9 phenol, dodecyl-, branched; [1]
phenol, 2-dodecyl-, branched; [2]
phenol, 3-dodecyl-, branched; [3]
phenol, 4-dodecyl-, branched; [4]
phenol, (tetrapropenyl) derivatives [5]
310-154-3 [1]
[2]
[3]
[4]
[5]
121158-58-5 [1]
[2]
[3]
210555-94-5 [4]
74499-35-7 [5]
Repr. 1B
Skin Corr. 1C
Eye Dam. 1
Aquatic Acute 1 Aquatic Chronic 1
H360F
H314
H318
H400
H410
GHS08
GHS05
GHS09
Dgr
H360F
H314
H410
M = 10
M = 10’
‘605-013-00-0 chloralose (INN);
(R)-1,2-O-(2,2,2-trichloroethylidene)-α-D-glucofuranose; glucochloralose; anhydroglucochloral
240-016-7 15879-93-3 Acute Tox. 4*
Acute Tox. 3
STOT SE 3
Aquatic Acute 1
Aquatic Chronic 1
H332
H301
H336
H400
H410
GHS06
GHS09
Dgr
H332
H301
H336
H410
M = 10
M = 10
C’ ‘605-022-00-X glutaral; glutaraldehyde;
1,5-pentanedial
203-856-5 111-30-8 Acute Tox. 2
Acute Tox. 3
STOT SE 3
Skin Corr. 1B
Resp. Sens. 1
Skin Sens. 1A
Aquatic Acute 1
Aquatic Chronic 2
H330
H301
H335
H314
H334
H317
H400
H411
GHS06
GHS05
GHS08
GHS09
Dgr
H330
H301
H335
H314
H334
H317
H410
EUH071 STOT SE 3; H335: 0,5 % ≤ C < 5 %
M = 1’
‘606-014-00-9 chlorophacinone (ISO);
2-[(4-chlorophenyl)(phenyl)acetyl]-1H-indene-1,3(2H)-dione
223-003-0 3691-35-8 Repr. 1B
Acute Tox. 1
Acute Tox. 1
Acute Tox. 1
STOT RE 1
Aquatic Acute 1
Aquatic Chronic 1
H360D
H330
H310
H300
H372 (blood)
H400
H410
GHS08
GHS06
GHS09
Dgr
H360D
H330
H310
H300
H372 (blood)
H410
Repr. 1B; H360D:
C ≥ 0,003 %
STOT RE 1; H372 (blood): C ≥ 0,1 %
STOT RE 2; H373 (blood):
0,01 % ≤ C < 0,1 %
M = 1
M = 1’
‘606-021-00-7 N-methyl-2-pyrrolidone; 1-methyl-2-pyrrolidone 212-828-1 872-50-4 Repr. 1B
STOT SE 3
Skin Irrit. 2
Eye Irrit. 2
H360D***
H335
H315
H319
GHS08
GHS07
Dgr
H360D***
H335
H315
H319
STOT SE 3; H335: C ≥ 10 %’ ‘607-056-00-0 warfarin (ISO);
4-hydroxy-3-(3-oxo-1-phenylbutyl)-2H-chromen-2-one; [1]
(S)-4-hydroxy-3-(3-oxo-1-phenylbutyl)-2-benzopyrone; [2]
(R)-4-hydroxy-3-(3-oxo-1-phenylbutyl)-2-benzopyrone [3]
201-377-6
[1]
226-907-3
[2]
226-908-9
[3]
81-81-2 [1]
5543-57-7
[2]
5543-58-8
[3]
Repr. 1A
Acute Tox. 1
Acute Tox. 1
Acute Tox. 2
STOT RE 1
Aquatic Chronic 2
H360D
H330
H310
H300
H372 (blood)
H411
GHS08
GHS06
GHS09
Dgr
H360D
H330
H310
H300
H372 (blood)
H411
Repr. 1A; H360D:
C ≥ 0,003 %
STOT RE 1; H372 (blood): C ≥ 0,5 %
STOT RE 2; H373 (blood): 0,05 % ≤ C < 0,5 %’
‘607-059-00-7 coumatetralyl (ISO); 4-hydroxy-3-(1,2,3,4-tetrahydro-1-naphthyl)coumarin 227-424-0 5836-29-3 Repr. 1B
Acute Tox. 2
Acute Tox. 3
Acute Tox. 2
STOT RE 1
Aquatic Chronic 1
H360D
H330
H311
H300
H372 (blood)
H410
GHS08
GHS06
GHS09
Dgr
H360D
H330
H311
H300
H372 (blood)
H410
Repr. 1B; H360D: C ≥ 0,003 %
STOT RE 1; H372 (blood): C ≥ 1,0 %
STOT RE 2; H373 (blood) 0,1 % ≤ C < 1,0 %
M = 10’
‘607-157-00-X difenacoum (ISO); 3-(3-biphenyl-4-yl-1,2,3,4-tetrahydro-1-naphthyl)-4-hydroxycoumarin 259-978-4 56073-07-5 Repr. 1B
Acute Tox. 1
Acute Tox. 1
Acute Tox. 1
STOT RE 1
Aquatic Acute 1
Aquatic Chronic 1
H360D
H330
H310
H300
H372 (blood)
H400
H410
GHS08
GHS06
GHS09
Dgr
H360D
H330
H310
H300
H372 (blood)
H410
Repr. 1B; H360D:
C ≥ 0,003 %
STOT RE 1; H372 (blood): C ≥ 0,02 % STOT RE 2; H373 (blood):
0,002 % ≤ C < 0,02 %
M = 10
M = 10’
‘607-172-00-1 brodifacoum (ISO);
4-hydroxy-3-(3-(4′-bromo-4-biphenylyl)-1,2,3,4-tetrahydro-1-naphthyl)coumarin
259-980-5 56073-10-0 Repr. 1A
Acute Tox. 1
Acute Tox. 1
Acute Tox. 1
STOT RE 1
Aquatic Acute 1
Aquatic Chronic 1
H360D
H330
H310
H300
H372 (blood)
H400
H410
GHS08
GHS06
GHS09
Dgr
H360D
H330
H310
H300
H372 (blood)
H410
Repr. 1A; H360D:
C ≥ 0,003 %
STOT RE 1; H372 (blood): C ≥ 0,02 % STOT RE 2; H373 (blood):
0,002 % ≤ C < 0,02 %
M = 10
M = 10’
‘607-375-00-5 flocoumafen (ISO); reaction mass of: cis-4-hydroxy-3-(1,2,3,4-tetrahydro-3-(4-(4-trifluoromethylbenzyloxy)phenyl)-1-naphthyl)coumarin and trans-4-hydroxy-3-(1,2,3,4-tetrahydro-3-(4-(4-trifluoromethylbenzyloxy)phenyl)-1-naphthyl)coumarin 421-960-0 90035-08-8 Repr. 1B
Acute Tox. 1
Acute Tox. 1
Acute Tox. 1
STOT RE 1
Aquatic Acute 1
Aquatic Chronic 1
H360D
H330
H310
H300
H372 (blood)
H400
H410
GHS08
GHS06
GHS09
Dgr
H360D
H330
H310
H300
H372 (blood)
H410
Repr. 1B; H360D:
C ≥ 0,003 %
STOT RE 1; H372 (blood): C ≥ 0,05 %
STOT RE 2; H373 (blood):
0,005 % ≤ C < 0,05 %
M = 10
M = 10’
‘607-623-00-2 diisobutyl phthalate 201-553-2 84-69-5 Repr. 1B H360Df GHS08
Dgr
H360Df’ ‘613-166-00-X flumioxazin (ISO);
2-[7-fluoro-3-oxo-4-(prop-2-yn-1-yl)-3,4-dihydro-2H-1,4-benzoxazin-6-yl]-4,5,6,7-tetrahydro-1H-isoindole-1,3(2H)-dione
— 103361-09-7 Repr. 1B
Aquatic Acute 1
Aquatic Chronic 1
H360D
H400
H410
GHS08
GHS09
Dgr
H360D
H410
M = 1 000
M = 1 000’
‘613-121-00-4 chlorsulfuron (ISO); 2-chloro-N-[[(4-methoxy-6-methyl-1,3,5-triazin-2- yl)amino]carbonyl]benzenesulphonamide 265-268-5 64902-72-3 Aquatic Acute 1
Aquatic Chronic 1
H400
H410
GHS09
Wng
H410 M = 1 000
M = 100’
‘616-011-00-4 N,N-dimethylacetamide 204-826-4 127-19-5 Repr. 1B
Acute Tox. 4*
Acute Tox. 4*
H360D***
H332
H312
GHS08
GHS07
Dgr
H360D***
H332
H312’
‘616-037-00-6 acetochlor (ISO); 2-chloro-N-(ethoxymethyl)-N-(2-ethyl-6-methylphenyl)acetamide 251-899-3 34256-82-1 Carc. 2
Repr. 2
Acute Tox. 4
STOT SE 3
STOT RE 2
Skin Irrit. 2
Skin Sens. 1
Aquatic Acute 1
Aquatic Chronic 1
H351
H361f
H332
H335
H373 (kidney)
H315
H317
H400
H410
GHS08
GHS07
GHS09
Wng
H351
H361f
H332
H335
H373 (kidney)
H315
H317
H410
M = 1 000
M = 100’
‘616-207-00-X polyhexamethylene biguanide hydrochloride;
PHMB
— 32289-58-0
27083-27-8
Carc. 2
Acute Tox. 2
Acute Tox. 4
STOT RE 1
Eye Dam. 1
Skin Sens. 1B
Aquatic Acute 1
Aquatic Chronic 1
H351
H330
H302
H372 (respiratory tract) (inhalation)
H318
H317
H400
H410
GHS08
GHS06
GHS05
GHS09
Dgr
H351
H330
H302
H372 (respiratory tract) (inhalation)
H318
H317
H410
M = 10
M = 10’
- (c)
the following entries are inserted in accordance with the order of the index numbers:
Index No International Chemical Identification EC No CAS No Classification Labelling Specific Conc. Limits, M-factors Notes Hazard Class and Category Code(s) Hazard statement Code(s) Pictogram, Signal Word Code(s) Hazard statement Code(s) Suppl. Hazard statement Code(s) ‘005-020-00-3 disodium octaborate anhydrous; [1]
disodium octaborate tetrahydrate [2]
234-541-0 [1]
234-541-0 [2]
12008-41-2 [1]
12280-03-4 [2]
Repr. 1B H360FD GHS08
Dgr
H360FD’ ‘014-046-00-4 e-glass microfibres of representative composition; [Calcium-aluminium-silicate fibres with random orientation with the following representative composition (% given by weight): SiO2 50,0-56,0 %, Al2O3 13,0-16,0 %, B2O3 5,8-10,0 %, Na2O < 0,6 %, K2O < 0,4 %, CaO 15,0-24,0 %, MgO < 5,5 %, Fe2O3 < 0,5 %, F2 < 1,0 %. Process: typically produced by flame attenuation and rotary process. (Additional individual elements may be present at low levels; the process list does not preclude innovation).] — — Carc. 1B H350i GHS08
Dgr
H350i A’ ‘014-047-00-X glass microfibres of representative composition; [Calcium-aluminium-silicate fibres with random orientation with the following composition (% given by weight): SiO2 55,0-60,0 %, Al2O3 4,0-7,0 %, B2O3 8,0-11,0 %, ZrO2 0,0-4,0 %, Na2O 9,5-13,5 %, K2O 0,0-4,0 %, CaO 1,0-5,0 %, MgO 0,0-2,0 %, Fe2O3 < 0,2 %, ZnO 2,0-5,0 %, BaO 3,0-6,0 %, F2 < 1,0 %. Process: typically produced by flame attenuation and rotary process. (Additional individual elements may be present at low levels; the process list does not preclude innovation).] — — Carc. 2 H351 (inhalation) GHS08
Wng
H351 (inhalation) A’ ‘029-015-00-0 copper thiocyanate 214-183-1 1111-67-7 Aquatic Acute 1 Aquatic Chronic 1 H400
H410
GHS09
Wng
H410 EUH032 M = 10’ ‘029-016-00-6 copper(II) oxide 215-269-1 1317-38-0 Aquatic Acute 1
Aquatic Chronic 1
H400
H410
GHS09
Wng
H410 M = 100’ ‘029-017-00-1 dicopper chloride trihydroxide 215-572-9 1332-65-6 Acute Tox. 4
Acute Tox. 3
Aquatic Acute 1
Aquatic Chronic 1
H332
H301
H400
H410
GHS06
GHS09
Dgr
H332
H301
H410
M = 10’ ‘029-018-00-7 tetracopper hexahydroxide sulphate; [1]
tetracopper hexahydroxide sulphate hydrate [2]
215-582-3 [1]
215-582-3 [2]
1333-22-8 [1]
12527-76-3 [2]
Acute Tox. 4
Aquatic Acute 1 Aquatic Chronic 1
H302
H400
H410
GHS07
GHS09
Wng
H302
H410
M = 10’ ‘029-019-01-X copper flakes (coated with aliphatic acid) — — Acute Tox. 3
Acute Tox. 4
Eye Irrit. 2
Aquatic Acute 1
Aquatic Chronic 1
H331
H302
H319
H400
H410
GHS06
GHS09
Dgr
H331
H302
H319
H410
M = 10’ ‘029-020-00-8 copper(II) carbonate--copper(II) hydroxide (1:1) 235-113-6 12069-69-1 Acute Tox. 4
Acute Tox. 4
Eye Irrit. 2
Aquatic Acute 1
Aquatic Chronic 1
H332
H302
H319
H400
H410
GHS07
GHS09
Wng
H332
H302
H319
H410
M = 10’ ‘029-021-00-3 copper dihydroxide;
copper(II) hydroxide
243-815-9 20427-59-2 Acute Tox. 2
Acute Tox. 4
Eye Dam. 1
Aquatic Acute 1
Aquatic Chronic 1
H330
H302
H318
H400
H410
GHS06
GHS05
GHS09
Dgr
H330
H302
H318
H410
M = 10’ ‘029-022-00-9 bordeaux mixture;
reaction products of copper sulphate with calcium dihydroxide
— 8011-63-0 Acute Tox. 4
Eye Dam. 1
Aquatic Acute 1
Aquatic Chronic 1
H332
H318
H400
H410
GHS07
GHS05
GHS09
Dgr
H332
H318
H410
M = 10’ ‘029-023-00-4 copper sulphate pentahydrate 231-847-6 7758-99-8 Acute Tox. 4
Eye Dam. 1
Aquatic Acute 1
Aquatic Chronic 1
H302
H318
H400
H410
GHS07
GHS05
GHS09
Dgr
H302
H318
H410
M = 10’ ‘082-013-00-1 lead powder;
[particle diameter < 1 mm]
231-100-4 7439-92-1 Repr. 1A
Lact.
H360FD
H362
GHS08
Dgr
H360FD
H362
Repr. 1A; H360D: C ≥ 0,03 %’ ‘082-014-00-7 lead massive:
[particle diameter ≥ 1 mm]
231-100-4 7439-92-1 Repr. 1A
Lact.
H360FD
H362
GHS08
Dgr
H360FD
H362’
‘605-040-00-8 hydroxyisohexyl 3-cyclohexene carboxaldehyde (INCI); reaction mass of 4-(4-hydroxy-4-methylpentyl)cyclohex-3-ene-1-carbaldehyde and 3-(4-hydroxy-4-methylpentyl)cyclohex-3-ene-1-carbaldehyde; [1]
4-(4-hydroxy-4-methylpentyl)cyclohex-3-ene-1-carbaldehyde; [2]
3-(4-hydroxy-4-methylpentyl)cyclohex-3-ene-1-carbaldehyde [3]
- [1]
250-863-4 [2]
257-187-9 [3]
130066-44-3 [1]
31906-04-4 [2]
51414-25-6 [3]
Skin Sens. 1A H317 GHS07
Wng
H317’ ‘607-716-00-8 bromadiolone (ISO); 3-[3-(4′-bromobiphenyl-4-yl)-3-hydroxy-1-phenylpropyl]-4-hydroxy-2H-chromen-2-one 249-205-9 28772-56-7 Repr. 1B
Acute Tox. 1
Acute Tox. 1
Acute Tox. 1
STOT RE 1
Aquatic Acute 1
Aquatic Chronic 1
H360D
H330
H310
H300
H372 (blood)
H400
H410
GHS08
GHS06
GHS09
Dgr
H360D
H330
H310
H300
H372 (blood)
H410
Repr. 1B; H360D:
C ≥ 0,003 %
STOT RE 1; H372 (blood): C ≥ 0,005 % STOT RE 2; H373 (blood):
0,0005 % ≤ C < 0,005 %
M = 1
M = 1’
‘607-717-00-3 difethialone (ISO);
3-[3-(4′-bromobiphenyl-4-yl)-1,2,3,4-tetrahydronaphthalen-1-yl]-4-hydroxy-2H-1-benzothiopyran-2-one
— 104653-34-1 Repr. 1B
Acute Tox. 1
Acute Tox. 1
Acute Tox. 1
STOT RE 1
Aquatic Acute 1
Aquatic Chronic 1
H360D
H330
H310
H300
H372 (blood)
H400
H410
GHS08
GHS06
GHS09
Dgr
H360D
H330
H310
H300
H372 (blood)
H410
EUH070 Repr. 1B; H360D:
C ≥ 0,003 %
STOT RE 1; H372 (blood): C ≥ 0,02 % STOT RE 2; H373 (blood):
0,002 % ≤ C < 0,02 %
M = 100
M = 100’
‘607-718-00-9 perfluorononan-1-oic acid [1] and its sodium [2] and ammonium [3] salts 206-801-3 [1]
[2]
[3]
375-95-1 [1]
21049-39-8 [2]
4149-60-4 [3]
Carc. 2
Repr. 1B
Lact.
Acute Tox. 4
Acute Tox. 4
STOT RE 1
Eye Dam. 1
H351
H360Df
H362
H332
H302
H372 (liver, thymus, spleen)
H318
GSH08
GSH07
GHS05
Dgr
H351
H360Df
H362
H332
H302
H372 (liver, thymus, spleen)
H318’
‘607-719-00-4 dicyclohexyl phthalate 201-545-9 84-61-7 Repr. 1B
Skin Sens. 1
H360D
H317
GHS08
GHS07
Dgr
H360D
H317’
‘608-067-00-3 3,7-dimethylocta-2,6-dienenitrile 225-918-0 5146-66-7 Muta. 1B H340 GHS08
Dgr
H340’ ‘612-288-00-0 bupirimate (ISO);
5-butyl-2-ethylamino-6-methylpyrimidin-4-yl dimethylsulphamate
255-391-2 41483-43-6 Carc. 2
Skin Sens. 1B
Aquatic Chronic 1
H351
H317
H410
GHS08
GHS07
GHS09
Wng
H351
H317
H410
M = 1’ ‘612-289-00-6 triflumizole (ISO);
(1E)-N-[4-chloro-2-(trifluoromethyl)phenyl]-1-(1H-imidazol-1-yl)-2-propoxyethanimine
— 68694-11-1 Repr. 1B
Acute Tox. 4
STOT RE 2
Skin Sens. 1
Aquatic Acute 1
Aquatic Chronic 1
H360D
H302
H373 (liver)
H317
H400
H410
GHS08
GHS07
GHS09
Dgr
H360D
H302
H373 (liver)
H317
H410
M = 1
M = 1’
‘616-218-00-X benzovindiflupyr (ISO); N-[9-(dichloromethylene)-1,2,3,4-tetrahydro-1,4-methanonaphthalen-5-yl]-3-(difluoromethyl)-1-methyl-1H-pyrazole-4-carboxamide — 1072957-71-1 Acute Tox. 3
Acute Tox. 3
Aquatic Acute 1
Aquatic Chronic 1
H331
H301
H400
H410
GHS06
GHS09
Dgr
H331
H301
H410
M = 100
M = 100’
‘616-219-00-5 fluopyram (ISO); N-{2-[3-chloro-5-(trifluoromethyl)pyridin-2-yl]ethyl}-2-(trifluoromethyl)benzamide — 658066-35-4 Aquatic Chronic 2 H411 GHS09 H411’ ‘616-220-00-0 pencycuron (ISO); 1-[(4-chlorophenyl)methyl]-1-cyclopentyl-3-phenylurea 266-096-3 66063-05-6 Aquatic Acute 1
Aquatic Chronic 1
H400
H410
GHS09
Wng
H410 M = 1
M = 1’
‘617-023-00-2 tert-butyl hydroperoxide 200-915-7 75-91-2 Muta. 2 H341 GHS08
Wng
H341’